{"entity":{"type":"insider","cik":"0001532219","url":"/insider/0001532219","json_url":"/insider/0001532219.json","name":"Quinn Anthony G.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":49,"n_filings":24,"first":"2012-06-27","last":"2025-01-14","span_basis":"filed_date"},"name_variants":[{"name":"Quinn Anthony G.","source":"filing","n_filings":12,"first_seen":"2017-12-05","last_seen":"2025-01-14"},{"name":"Quinn Anthony","source":"filing","n_filings":12,"first_seen":"2012-06-27","last_seen":"2016-04-12"}],"transactions":[{"id":4466184,"accession":"0001415889-25-001417","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-001417","line_url":"/filing/0001415889-25-001417#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Generation Bio Co.","issuer_ticker":"GBIO","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":85000.0,"shares_display":"85,000","price_per_share":0.97,"price_display":"0.97","price_state":"stated","total_value":82450.0,"total_display":"82,450.00","total_whole":"82,450","shares_owned_after":299286.0,"shares_owned_after_display":"299,286","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-13","filed_date":"2025-01-14","scope":"insider"},{"id":4466179,"accession":"0001415889-25-001417","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-001417","line_url":"/filing/0001415889-25-001417#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Generation Bio Co.","issuer_ticker":"GBIO","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":125791.0,"shares_display":"125,791","price_per_share":0.96,"price_display":"0.96","price_state":"stated","total_value":120759.36,"total_display":"120,759.36","total_whole":"120,759","shares_owned_after":214286.0,"shares_owned_after_display":"214,286","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-10","filed_date":"2025-01-14","scope":"insider"},{"id":8764305,"accession":"0001415889-23-015857","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-23-015857","line_url":"/filing/0001415889-23-015857#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Generation Bio Co.","issuer_ticker":"GBIO","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":88495.0,"shares_display":"88,495","price_per_share":1.41,"price_display":"1.41","price_state":"stated","total_value":124777.95,"total_display":"124,777.95","total_whole":"124,778","shares_owned_after":88495.0,"shares_owned_after_display":"88,495","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-01","filed_date":"2023-12-05","scope":"insider"},{"id":6978251,"accession":"0001209191-22-019929","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-019929","line_url":"/filing/0001209191-22-019929#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":80079.0,"shares_display":"80,079","price_per_share":2.344,"price_display":"2.34","price_state":"stated","total_value":187705.176,"total_display":"187,705.18","total_whole":"187,705","shares_owned_after":550540.0,"shares_owned_after_display":"550,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-16","filed_date":"2022-03-18","scope":"insider"},{"id":6424925,"accession":"0001209191-22-018942","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-018942","line_url":"/filing/0001209191-22-018942#line-3","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":42417.0,"shares_display":"42,417","price_per_share":1.8611,"price_display":"1.86","price_state":"stated","total_value":78942.2787,"total_display":"78,942.28","total_whole":"78,942","shares_owned_after":473461.0,"shares_owned_after_display":"473,461","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-15","filed_date":"2022-03-15","scope":"insider"},{"id":6424922,"accession":"0001209191-22-018942","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-018942","line_url":"/filing/0001209191-22-018942#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":67472.0,"shares_display":"67,472","price_per_share":1.93,"price_display":"1.93","price_state":"stated","total_value":130220.96,"total_display":"130,220.96","total_whole":"130,221","shares_owned_after":431044.0,"shares_owned_after_display":"431,044","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-14","filed_date":"2022-03-15","scope":"insider"},{"id":6424919,"accession":"0001209191-22-018942","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-018942","line_url":"/filing/0001209191-22-018942#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34777.0,"shares_display":"34,777","price_per_share":2.064,"price_display":"2.06","price_state":"stated","total_value":71779.728,"total_display":"71,779.73","total_whole":"71,780","shares_owned_after":363572.0,"shares_owned_after_display":"363,572","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-11","filed_date":"2022-03-15","scope":"insider"},{"id":5016135,"accession":"0001209191-21-069350","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-069350","line_url":"/filing/0001209191-21-069350#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10526.0,"shares_display":"10,526","price_per_share":3.75,"price_display":"3.75","price_state":"stated","total_value":39472.5,"total_display":"39,472.50","total_whole":"39,473","shares_owned_after":328795.0,"shares_owned_after_display":"328,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-10","filed_date":"2021-12-13","scope":"insider"},{"id":5016131,"accession":"0001209191-21-069350","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-069350","line_url":"/filing/0001209191-21-069350#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":43108.0,"shares_display":"43,108","price_per_share":3.7,"price_display":"3.70","price_state":"stated","total_value":159499.6,"total_display":"159,499.60","total_whole":"159,500","shares_owned_after":318269.0,"shares_owned_after_display":"318,269","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-09","filed_date":"2021-12-13","scope":"insider"},{"id":2075970,"accession":"0001209191-20-026662","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-026662","line_url":"/filing/0001209191-20-026662#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":165000.0,"shares_display":"165,000","price_per_share":4.75,"price_display":"4.75","price_state":"stated","total_value":783750.0,"total_display":"783,750.00","total_whole":"783,750","shares_owned_after":538469.0,"shares_owned_after_display":"538,469","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-04-30","filed_date":"2020-05-04","scope":"insider"},{"id":7868706,"accession":"0001567619-19-013411","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-19-013411","line_url":"/filing/0001567619-19-013411#line-3","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5282.0,"shares_display":"5,282","price_per_share":6.2311,"price_display":"6.23","price_state":"stated","total_value":32912.6702,"total_display":"32,912.67","total_whole":"32,913","shares_owned_after":353643.0,"shares_owned_after_display":"353,643","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-14","filed_date":"2019-06-14","scope":"insider"},{"id":7868703,"accession":"0001567619-19-013411","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-013411","line_url":"/filing/0001567619-19-013411#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14406.0,"shares_display":"14,406","price_per_share":6.1666,"price_display":"6.17","price_state":"stated","total_value":88836.0396,"total_display":"88,836.04","total_whole":"88,836","shares_owned_after":348361.0,"shares_owned_after_display":"348,361","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-13","filed_date":"2019-06-14","scope":"insider"},{"id":7868700,"accession":"0001567619-19-013411","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-19-013411","line_url":"/filing/0001567619-19-013411#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12217.0,"shares_display":"12,217","price_per_share":6.1148,"price_display":"6.11","price_state":"stated","total_value":74704.5116,"total_display":"74,704.51","total_whole":"74,705","shares_owned_after":333955.0,"shares_owned_after_display":"333,955","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-12","filed_date":"2019-06-14","scope":"insider"},{"id":7825397,"accession":"0001567619-19-011852","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-19-011852","line_url":"/filing/0001567619-19-011852#line-3","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3809.0,"shares_display":"3,809","price_per_share":6.8596,"price_display":"6.86","price_state":"stated","total_value":26128.2164,"total_display":"26,128.22","total_whole":"26,128","shares_owned_after":321738.0,"shares_owned_after_display":"321,738","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-22","filed_date":"2019-05-22","scope":"insider"},{"id":7825394,"accession":"0001567619-19-011852","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-011852","line_url":"/filing/0001567619-19-011852#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13794.0,"shares_display":"13,794","price_per_share":6.8857,"price_display":"6.89","price_state":"stated","total_value":94981.3458,"total_display":"94,981.35","total_whole":"94,981","shares_owned_after":317929.0,"shares_owned_after_display":"317,929","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-21","filed_date":"2019-05-22","scope":"insider"},{"id":7825391,"accession":"0001567619-19-011852","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-19-011852","line_url":"/filing/0001567619-19-011852#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8989.0,"shares_display":"8,989","price_per_share":6.555,"price_display":"6.56","price_state":"stated","total_value":58922.895,"total_display":"58,922.90","total_whole":"58,923","shares_owned_after":304135.0,"shares_owned_after_display":"304,135","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-20","filed_date":"2019-05-22","scope":"insider"},{"id":8336439,"accession":"0001567619-19-011561","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567619-19-011561","line_url":"/filing/0001567619-19-011561#line-4","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6218.0,"shares_display":"6,218","price_per_share":6.6477,"price_display":"6.65","price_state":"stated","total_value":41335.3986,"total_display":"41,335.40","total_whole":"41,335","shares_owned_after":295146.0,"shares_owned_after_display":"295,146","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-17","filed_date":"2019-05-17","scope":"insider"},{"id":8336434,"accession":"0001567619-19-011561","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-19-011561","line_url":"/filing/0001567619-19-011561#line-3","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5520.0,"shares_display":"5,520","price_per_share":6.828,"price_display":"6.83","price_state":"stated","total_value":37690.56,"total_display":"37,690.56","total_whole":"37,691","shares_owned_after":288928.0,"shares_owned_after_display":"288,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-16","filed_date":"2019-05-17","scope":"insider"},{"id":8336427,"accession":"0001567619-19-011561","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-011561","line_url":"/filing/0001567619-19-011561#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6256.0,"shares_display":"6,256","price_per_share":6.7566,"price_display":"6.76","price_state":"stated","total_value":42269.2896,"total_display":"42,269.29","total_whole":"42,269","shares_owned_after":283408.0,"shares_owned_after_display":"283,408","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-15","filed_date":"2019-05-17","scope":"insider"},{"id":8336420,"accession":"0001567619-19-011561","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-19-011561","line_url":"/filing/0001567619-19-011561#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":719.0,"shares_display":"719","price_per_share":7.098,"price_display":"7.10","price_state":"stated","total_value":5103.462,"total_display":"5,103.46","total_whole":"5,103","shares_owned_after":277152.0,"shares_owned_after_display":"277,152","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-15","filed_date":"2019-05-17","scope":"insider"},{"id":6078422,"accession":"0001567619-18-007640","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-18-007640","line_url":"/filing/0001567619-18-007640#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":994.0,"shares_display":"994","price_per_share":9.13,"price_display":"9.13","price_state":"stated","total_value":9075.22,"total_display":"9,075.22","total_whole":"9,075","shares_owned_after":95787.0,"shares_owned_after_display":"95,787","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-15","filed_date":"2018-12-10","scope":"insider"},{"id":6078420,"accession":"0001567619-18-007640","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-18-007640","line_url":"/filing/0001567619-18-007640#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":6.02,"price_display":"6.02","price_state":"stated","total_value":12040.0,"total_display":"12,040.00","total_whole":"12,040","shares_owned_after":94793.0,"shares_owned_after_display":"94,793","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-02-15","filed_date":"2018-12-10","scope":"insider"},{"id":4788872,"accession":"0001140361-17-045528","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-17-045528","line_url":"/filing/0001140361-17-045528#line-3","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (Interim CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":600.0,"shares_display":"600","price_per_share":5.065,"price_display":"5.06","price_state":"stated","total_value":3039.0,"total_display":"3,039.00","total_whole":"3,039","shares_owned_after":35409.0,"shares_owned_after_display":"35,409","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-08","filed_date":"2017-12-08","scope":"insider"},{"id":4788867,"accession":"0001140361-17-045528","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-17-045528","line_url":"/filing/0001140361-17-045528#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (Interim CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2800.0,"shares_display":"2,800","price_per_share":4.9882,"price_display":"4.99","price_state":"stated","total_value":13966.96,"total_display":"13,966.96","total_whole":"13,967","shares_owned_after":34809.0,"shares_owned_after_display":"34,809","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-07","filed_date":"2017-12-08","scope":"insider"},{"id":4788863,"accession":"0001140361-17-045528","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-045528","line_url":"/filing/0001140361-17-045528#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director, Officer (Interim CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4888.0,"shares_display":"4,888","price_per_share":4.9248,"price_display":"4.92","price_state":"stated","total_value":24072.4224,"total_display":"24,072.42","total_whole":"24,072","shares_owned_after":32009.0,"shares_owned_after_display":"32,009","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-06","filed_date":"2017-12-08","scope":"insider"},{"id":4459300,"accession":"0001140361-17-045127","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-17-045127","line_url":"/filing/0001140361-17-045127#line-3","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5065.0,"shares_display":"5,065","price_per_share":4.931,"price_display":"4.93","price_state":"stated","total_value":24975.515,"total_display":"24,975.52","total_whole":"24,976","shares_owned_after":27121.0,"shares_owned_after_display":"27,121","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-05","filed_date":"2017-12-05","scope":"insider"},{"id":4459294,"accession":"0001140361-17-045127","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-17-045127","line_url":"/filing/0001140361-17-045127#line-2","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7956.0,"shares_display":"7,956","price_per_share":4.9804,"price_display":"4.98","price_state":"stated","total_value":39624.0624,"total_display":"39,624.06","total_whole":"39,624","shares_owned_after":22056.0,"shares_owned_after_display":"22,056","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-04","filed_date":"2017-12-05","scope":"insider"},{"id":4459289,"accession":"0001140361-17-045127","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-045127","line_url":"/filing/0001140361-17-045127#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony G.","owner_display_name":"Quinn Anthony G.","owner_url":"/insider/0001532219","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4100.0,"shares_display":"4,100","price_per_share":4.5312,"price_display":"4.53","price_state":"stated","total_value":18577.92,"total_display":"18,577.92","total_whole":"18,578","shares_owned_after":14100.0,"shares_owned_after_display":"14,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-01","filed_date":"2017-12-05","scope":"insider"},{"id":2474268,"accession":"0001140361-16-060931","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-16-060931","line_url":"/filing/0001140361-16-060931#line-1","is_derivative":false,"issuer_cik":"0001532219","issuer_name":"Aeglea BioTherapeutics, Inc.","issuer_ticker":"AGLE","issuer_name_source":null,"issuer_url":"/issuer/0001532219","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":100000.0,"total_display":"100,000.00","total_whole":"100,000","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-12","filed_date":"2016-04-12","scope":"insider"},{"id":8661045,"accession":"0001246360-15-001885","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-15-001885","line_url":"/filing/0001246360-15-001885#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (EVP, CMO & Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP, CMO & Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CMO & Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":110.0,"price_display":"110.00","price_state":"stated","total_value":1100000.0,"total_display":"1,100,000.00","total_whole":"1,100,000","shares_owned_after":5637.0,"shares_owned_after_display":"5,637","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-27","filed_date":"2015-04-29","scope":"insider"},{"id":8728660,"accession":"0001246360-15-001833","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001246360-15-001833","line_url":"/filing/0001246360-15-001833#line-1","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (EVP, CMO & Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP, CMO & Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CMO & Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":108.0,"price_display":"108.00","price_state":"stated","total_value":1080000.0,"total_display":"1,080,000.00","total_whole":"1,080,000","shares_owned_after":5637.0,"shares_owned_after_display":"5,637","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-21","filed_date":"2015-04-23","scope":"insider"},{"id":8935280,"accession":"0001246360-15-001816","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-15-001816","line_url":"/filing/0001246360-15-001816#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (EVP, CMO & Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP, CMO & Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CMO & Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":105.0,"price_display":"105.00","price_state":"stated","total_value":1050000.0,"total_display":"1,050,000.00","total_whole":"1,050,000","shares_owned_after":15637.0,"shares_owned_after_display":"15,637","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-15","filed_date":"2015-04-17","scope":"insider"},{"id":8193635,"accession":"0001246360-15-001755","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001246360-15-001755","line_url":"/filing/0001246360-15-001755#line-4","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (EVP, CMO & Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP, CMO & Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CMO & Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29503.0,"shares_display":"29,503","price_per_share":93.76,"price_display":"93.76","price_state":"stated","total_value":2766201.28,"total_display":"2,766,201.28","total_whole":"2,766,201","shares_owned_after":15637.0,"shares_owned_after_display":"15,637","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-06","filed_date":"2015-04-08","scope":"insider"},{"id":6536283,"accession":"0001246360-14-003716","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001246360-14-003716","line_url":"/filing/0001246360-14-003716","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (EVP, CMO & Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP, CMO & Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CMO & Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":70.1404,"price_display":"70.14","price_state":"stated","total_value":701404.0,"total_display":"701,404.00","total_whole":"701,404","shares_owned_after":26995.0,"shares_owned_after_display":"26,995","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-09-02","filed_date":"2014-09-04","scope":"insider","n_lines":4},{"id":6919026,"accession":"0001246360-14-002041","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001246360-14-002041","line_url":"/filing/0001246360-14-002041","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (EVP, CMO & Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP, CMO & Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CMO & Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":83.534531,"price_display":"83.53","price_state":"stated","total_value":1670690.62,"total_display":"1,670,690.62","total_whole":"1,670,691","shares_owned_after":24849.0,"shares_owned_after_display":"24,849","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-04-01","filed_date":"2014-04-03","scope":"insider","n_lines":4},{"id":5555335,"accession":"0001246360-13-000567","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-13-000567","line_url":"/filing/0001246360-13-000567#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (SVP, Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9447.0,"shares_display":"9,447","price_per_share":50.08,"price_display":"50.08","price_state":"stated","total_value":473105.76,"total_display":"473,105.76","total_whole":"473,106","shares_owned_after":15035.0,"shares_owned_after_display":"15,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-01-18","filed_date":"2013-01-23","scope":"insider"},{"id":4311836,"accession":"0001246360-13-000516","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001246360-13-000516","line_url":"/filing/0001246360-13-000516#line-4","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (SVP, Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":10000.0,"total_display":"10,000.00","total_whole":"10,000","shares_owned_after":15035.0,"shares_owned_after_display":"15,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-01-17","filed_date":"2013-01-18","scope":"insider"},{"id":4311829,"accession":"0001246360-13-000516","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-13-000516","line_url":"/filing/0001246360-13-000516#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (SVP, Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5353.0,"shares_display":"5,353","price_per_share":50.07,"price_display":"50.07","price_state":"stated","total_value":268024.71,"total_display":"268,024.71","total_whole":"268,025","shares_owned_after":15035.0,"shares_owned_after_display":"15,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-01-16","filed_date":"2013-01-18","scope":"insider"},{"id":2223661,"accession":"0001246360-12-003224","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001246360-12-003224","line_url":"/filing/0001246360-12-003224#line-4","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (SVP, Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6400.0,"shares_display":"6,400","price_per_share":50.2346,"price_display":"50.23","price_state":"stated","total_value":321501.44,"total_display":"321,501.44","total_whole":"321,501","shares_owned_after":20035.0,"shares_owned_after_display":"20,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-07-27","filed_date":"2012-07-30","scope":"insider"},{"id":2223655,"accession":"0001246360-12-003224","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-12-003224","line_url":"/filing/0001246360-12-003224#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (SVP, Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1100.0,"shares_display":"1,100","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":55000.0,"total_display":"55,000.00","total_whole":"55,000","shares_owned_after":20035.0,"shares_owned_after_display":"20,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-07-26","filed_date":"2012-07-30","scope":"insider"},{"id":3477111,"accession":"0001246360-12-003162","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001246360-12-003162","line_url":"/filing/0001246360-12-003162#line-4","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (SVP, Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":600.0,"shares_display":"600","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":30000.0,"total_display":"30,000.00","total_whole":"30,000","shares_owned_after":20035.0,"shares_owned_after_display":"20,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-07-20","filed_date":"2012-07-23","scope":"insider"},{"id":3477106,"accession":"0001246360-12-003162","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-12-003162","line_url":"/filing/0001246360-12-003162#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (SVP, Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1900.0,"shares_display":"1,900","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":95000.0,"total_display":"95,000.00","total_whole":"95,000","shares_owned_after":20035.0,"shares_owned_after_display":"20,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-07-19","filed_date":"2012-07-23","scope":"insider"},{"id":2801329,"accession":"0001246360-12-002852","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001246360-12-002852","line_url":"/filing/0001246360-12-002852#line-1","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532219","owner_name":"Quinn Anthony","owner_display_name":"Quinn Anthony","owner_url":"/insider/0001532219","role":"Officer (SVP, Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26000.0,"shares_display":"26,000","price_per_share":40.649,"price_display":"40.65","price_state":"stated","total_value":1056874.0,"total_display":"1,056,874.00","total_whole":"1,056,874","shares_owned_after":20035.0,"shares_owned_after_display":"20,035","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-06-25","filed_date":"2012-06-27","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":49,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":29,"open_market":true},{"code":"S","label":"Open-market sale","n":20,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":49},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001733294","name":"Generation Bio Co.","url":"/issuer/0001733294","role":"Director","n_filings":2,"first_seen":"2023-12-05","last_seen":"2025-01-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001636282","name":"Aeglea BioTherapeutics, Inc.","url":"/issuer/0001636282","role":"Director, Officer (President & CEO)","n_filings":11,"first_seen":"2016-04-12","last_seen":"2022-03-18"},{"type":"issuer","type_label":"ISSUER","cik":"0000911326","name":"SYNAGEVA BIOPHARMA CORP","url":"/issuer/0000911326","role":"Officer (EVP, CMO & Head of R&D)","n_filings":11,"first_seen":"2012-06-27","last_seen":"2015-04-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001532219","retrieved_at":"2026-08-23T22:35:14+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}